Compare · BIIB vs VOR
BIIB vs VOR
Side-by-side comparison of Biogen Inc. (BIIB) and Vor Biopharma Inc. (VOR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and VOR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $32.62B, about 23.0x VOR ($1.42B).
- BIIB has been more active in the news (9 items in the past 4 weeks vs 5 for VOR).
- BIIB has more recent analyst coverage (25 ratings vs 16 for VOR).
- Company
- Biogen Inc.
- Vor Biopharma Inc.
- Price
- -
- -
- Market cap
- $32.62B
- $1.42B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 9
- 5
- Recent ratings
- 25
- 16
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Vor Biopharma Inc.
Vor Biopharma, Inc., early-stage cell therapy company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Latest BIIB
- LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease
- LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
- Biogen upgraded by Wolfe Research with a new price target
- SEC Form 3 filed by new insider Parini Michael
- Biogen Completes Acquisition of RayThera Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.
- Director Minor Lloyd sold $239,750 worth of shares (1,186 units at $202.15), decreasing direct ownership by 31% to 2,689 units (SEC Form 4)
- Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
- Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
- SEC Form 10-Q filed by Biogen Inc.
Latest VOR
- Amendment: SEC Form SCHEDULE 13G/A filed by Vor Biopharma Inc.
- SEC Form 10-Q filed by Vor Biopharma Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Vor Biopharma Inc.
- SEC Form SCHEDULE 13G filed by Vor Biopharma Inc.
- Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Vor Biopharma Inc.
- Large owner Ra Capital Management, L.P. exercised 2,100,000 in-the-money shares at a strike of $0.00 and sold $4,207 worth of shares (213 units at $19.75) (SEC Form 4)
- SEC Form 4 filed by Director Zaccardelli David
- SEC Form 3 filed by new insider Zaccardelli David
- Vor Biopharma Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits